GET DAILY SIGNALSMAIA Biotechnology (MAIA): Monitoring Enrollment Progress in Its Pivotal Phase 3 Trial
Key Takeaways
- MAIA Biotechnology is a clinical-stage immuno-oncology company developing ateganosine (THIO), a first-in-class telomere-targeting therapy for non-small cell lung cancer (NSCLC).
- Shares have traded in a narrow range near $1.18 over the trailing 30 days, reflecting a period of consolidation rather than a sharp directional move.
- The company holds U.S. FDA Fast Track designation for ateganosine in NSCLC and is advancing both a Phase 2 (THIO-101) and a pivotal Phase 3 (THIO-104) program.
- Phase 3 THIO-104 reached 65 enrolled patients, or 65% of its year-end target of 100, with an interim survival analysis expected in 2027.
- A $33 million capital raise completed in early 2026 is expected to fully fund the pivotal Phase 3 trial, and insider open-market purchases signaled management alignment.
- As a pre-revenue development-stage biotech, MAIA carries elevated clinical, regulatory, and financing risk typical of the sector.
- For additional context, review MAIA's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies screen opportunities across the market.
Recent Price Action and Market Context
MAIA Biotechnology (MAIA) has held within a relatively tight band lately, with shares hovering near the $1.15 to $1.20 range. Over the past 30 days the stock has posted limited net movement, a contrast to the sharper swings seen during earlier stages of its clinical updates. At a market capitalization of roughly $70 million, MAIA remains a small-cap, pre-revenue name whose valuation hinges mainly on clinical and regulatory milestones rather than earnings. While broader biotech sentiment has been mixed, price action here has stayed anchored by company-specific news around the ateganosine program.
Company Overview and Competitive Landscape
Founded in 2018 and based in Chicago, MAIA Biotechnology focuses on targeted immunotherapies for cancer. Its lead candidate, ateganosine (THIO or 6-thio-2'-deoxyguanosine), is positioned as the only direct telomere-targeting anticancer agent in clinical development. The compound works through a dual mechanism, triggering telomerase-dependent DNA damage in cancer cells and stimulating innate and adaptive immune responses. Development centers on third-line treatment for advanced NSCLC after progression on checkpoint inhibitors and chemotherapy, an area with clear unmet need. The company maintains combination agreements with Roche (atezolizumab), BeOne Medicines (tislelizumab), and sequencing with Regeneron's cemiplimab (Libtayo). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key Clinical Updates and Execution
News flow over the past month has centered on steady enrollment across the two main trials. In September the company noted that its pivotal Phase 3 THIO-104 study had reached 65 patients, toward a target of more than 100 dosed by year-end 2026, with an interim analysis planned for 2027. Regulators in Spain and Portugal have cleared screening, expanding the European sites. October brought word that 150 patients had received ateganosine sequenced with a checkpoint inhibitor across the Phase 2 and Phase 3 programs, and that Part C enrollment in THIO-101 is now complete. Prior data showed a 90.5% disease control rate in the efficacy-evaluable Phase 2 group, compared with reported 25%–35% rates for standard third-line chemotherapy. A March 2026 financing of about $33 million is expected to cover the Phase 3 program fully, and disclosures showed insider open-market purchases in late summer 2026.
Looking Ahead to 2026 and Beyond
The main catalyst remains advancement of ateganosine through late-stage development. Investors will likely track enrollment toward the year-end 2026 goal of 100 dosed patients in THIO-104, along with any interim efficacy readouts from both studies. Regulatory steps under the FDA Fast Track designation, including possible routes to Accelerated Approval or Priority Review, stand out as important milestones. Other items to follow include the timing of the 2027 interim overall survival analysis, cash runway and any additional financing, and early data on second-generation telomere-targeting agents entering Phase 1. As with most clinical-stage biotechs, trial outcomes and regulatory decisions will drive both upside and downside.
Using AI Tools in Biotech Research
I’ve found Tickeron’s AI Trading Bots helpful for spotting systematic patterns across development-stage names like this one. The platform surfaces a range of strategies that can complement manual review of clinical timelines and financing events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MAIA's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for MAIA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In 19 of the 21 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 57 cases where MAIA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on MAIA as a result. In 80 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for MAIA just turned positive on October 22, 2026. Looking at past instances where MAIA's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.
Following a +6.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where MAIA advanced for three days, in 181 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
MAIA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
MAIA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MAIA crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MAIA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for MAIA entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.315) is normal, around the industry mean (2.974). P/E Ratio (-1.762) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. MAIA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MAIA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement